IDEAYA renews shelf, $156.6M ATM capacity
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
IDEAYA Biosciences, Inc. filed a new automatic shelf registration statement on Form S-3ASR and an at-the-market prospectus supplement that together cover potential common stock sales with aggregate gross proceeds of up to $156.6 million under its existing Open Market Sales Agreement with Jefferies LLC.
The new shelf replaces a prior automatic shelf that would have expired in June 2026, which is deemed terminated as of the new statement’s effective date. IDEAYA has previously sold common stock with an aggregate gross sales price of $193,447,003.19 under this agreement, and the remaining capacity is now available for discretionary future sales.
8-K Event Classification
Key Figures
Key Terms
automatic shelf registration statement regulatory
Form S-3ASR regulatory
Open Market Sales Agreement financial
ATM Prospectus Supplement regulatory
Rule 415(a)(5) regulatory
Rule 415(a)(6) regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did IDEAYA Biosciences (IDYA) file on May 5, 2026?
How large is IDEAYA Biosciences’ remaining ATM capacity under the Jefferies agreement?
How much stock has IDEAYA already sold through its ATM program?
What happened to IDEAYA’s prior automatic shelf registration statement?
What legal opinions support IDEAYA’s new ATM prospectus supplement?
AI-generated analysis. How Rhea-AI works. Not financial advice.